Literature DB >> 7704938

Use of tumor necrosis factor in isolated hepatic perfusion.

D L Fraker1, H R Alexander, A K Thom.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7704938

Source DB:  PubMed          Journal:  Circ Shock        ISSN： 0092-6213


× No keyword cloud information.
  5 in total

1.  Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs.

Authors:  M G van Ijken; E A de Bruijn; G de Boeck; T L ten Hagen; J R van der Sijp; A M Eggermont
Journal:  Ann Surg       Date:  1998-12       Impact factor: 12.969

2.  Flushing out antibodies to make AAV gene therapy available to more patients.

Authors:  Steven E Raper; James M Wilson; Frederick A Nunes
Journal:  Mol Ther       Date:  2013-02       Impact factor: 11.454

3.  Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.

Authors:  A M Eggermont; H Schraffordt Koops; J M Klausner; B B Kroon; P M Schlag; D Liénard; A N van Geel; H J Hoekstra; I Meller; O E Nieweg; C Kettelhack; G Ben-Ari; J C Pector; F J Lejeune
Journal:  Ann Surg       Date:  1996-12       Impact factor: 12.969

Review 4.  Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma.

Authors:  M M Walther; S B Jennings; P L Choyke; M Andrich; K Hurley; W M Linehan; S A Rosenberg; R B Alexander
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

5.  Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats.

Authors:  J H de Wilt; E R Manusama; S T van Tiel; M G van Ijken; T L ten Hagen; A M Eggermont
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.